Cost-utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-refractory Dermatomyositis in Thailand

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2015 Mar 17

PMID 25774016

Citations 6

Authors

Naruemon Bamrungsawad

Nathorn Chaiyakunapruk

Nilawan Upakdee

Chayanin Pratoomsoot

Rosarin Sruamsiri

Piyameth Dilokthornsakul

Affiliations

Soon will be listed here.

Abstract

Introduction: Intravenous immunoglobulin (IVIG) has been shown to be effective in treating steroid-refractory dermatomyositis (DM). There remains no evidence of its cost-effectiveness in Thailand.

Objective: Our objective was to estimate the cost utility of IVIG as a second-line therapy in steroid-refractory DM in Thailand.

Methods: A Markov model was developed to estimate the relevant costs and health benefits for IVIG plus corticosteroids in comparison with immunosuppressant plus corticosteroids in steroid-refractory DM from a societal perspective over a patient's lifetime. The effectiveness and utility parameters were obtained from clinical literature, meta-analyses, medical record reviews, and patient interviews, whereas cost data were obtained from an electronic hospital database and patient interviews. Costs are presented in $US, year 2012 values. All future costs and outcomes were discounted at a rate of 3% per annum. One-way and probabilistic sensitivity analyses were also performed.

Results: Over a lifetime horizon, the model estimated treatment under IVIG plus corticosteroids to be cost saving compared with immunosuppressant plus corticosteroids, where the saving of costs and incremental quality-adjusted life-years (QALYs) were $US4738.92 and 1.96 QALYs, respectively. Sensitivity analyses revealed that probability of response of immunosuppressant plus corticosteroids was the most influential parameter on incremental QALYs and costs. At a societal willingness-to-pay threshold in Thailand of $US5148 per QALY gained, the probability of IVIG being cost effective was 97.6%.

Conclusions: The use of IVIG plus corticosteroids is cost saving compared with treatment with immunosuppressant plus corticosteroids in Thai patients with steroid-refractory DM. Policy makers should consider using our findings in their decision-making process for adding IVIG to corticosteroids as the second-line therapy for steroid-refractory DM patients.

Citing Articles

Direct and indirect costs of idiopathic inflammatory myopathies in adults: A systematic review.

Daniel E, Smith I, Ly V, Bourque P, Breiner A, Lochmuller H PLoS One. 2024; 19(7):e0307144.

PMID: 39058702 PMC: 11280229. DOI: 10.1371/journal.pone.0307144.

Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Wu J, Lu M, Reed A World J Pediatr. 2019; 16(1):31-43.

PMID: 31556011 DOI: 10.1007/s12519-019-00313-8.

Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Pachman L, Khojah A J Pediatr. 2018; 195:16-27.

PMID: 29576174 PMC: 5881602. DOI: 10.1016/j.jpeds.2017.12.053.

Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Dourmishev L, Guleva D, Miteva L Wien Med Wochenschr. 2017; 168(9-10):213-217.

PMID: 28864939 DOI: 10.1007/s10354-017-0595-x.

A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.

Kotirum S, Chongmelaxme B, Chaiyakunapruk N J Thromb Thrombolysis. 2016; 43(2):252-262.

PMID: 27704332 DOI: 10.1007/s11239-016-1433-5.

References

Sigurgeirsson B, Lindelof B, Edhag O, Allander E . Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992; 326(6):363-7. DOI: 10.1056/NEJM199202063260602. View

Dalakas M . Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord. 2010; 1(3):157-66. PMC: 3002554. DOI: 10.1177/1756285608097463. View

Dalakas M, Hohlfeld R . Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. DOI: 10.1016/S0140-6736(03)14368-1. View

Cox S, Limaye V, Hill C, Blumbergs P, Roberts-Thomson P . Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int J Rheum Dis. 2010; 13(2):117-24. DOI: 10.1111/j.1756-185X.2010.01472.x. View

van de Vlekkert J, Hoogendijk J, de Visser M . Long-term follow-up of 62 patients with myositis. J Neurol. 2014; 261(5):992-8. DOI: 10.1007/s00415-014-7313-z. View

Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y . Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2011; 22(3):382-93. PMC: 3375426. DOI: 10.1007/s10165-011-0534-4. View

Dalakas M, Illa I, Dambrosia J, Soueidan S, Stein D, Otero C . A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993; 329(27):1993-2000. DOI: 10.1056/NEJM199312303292704. View

Furst D, Amato A, Iorga S, Gajria K, Fernandes A . Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012; 45(5):676-83. DOI: 10.1002/mus.23302. View

D Donofrio P, Berger A, Brannagan 3rd T, Bromberg M, Howard J, Latov N . Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009; 40(5):890-900. DOI: 10.1002/mus.21433. View

10.

Prieto S, Grau J . The geoepidemiology of autoimmune muscle disease. Autoimmun Rev. 2009; 9(5):A330-4. DOI: 10.1016/j.autrev.2009.11.006. View

11.

Callen J, Wortmann R . Dermatomyositis. Clin Dermatol. 2006; 24(5):363-73. DOI: 10.1016/j.clindermatol.2006.07.001. View

12.

Iorizzo 3rd L, Jorizzo J . The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008; 59(1):99-112. DOI: 10.1016/j.jaad.2008.02.043. View

13.

Klein-Gitelman M, Waters T, Pachman L . The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res. 2003; 13(6):360-8. DOI: 10.1002/1529-0131(200012)13:6<360::aid-art5>3.0.co;2-q. View

14.

Rider L, Werth V, Huber A, Alexanderson H, Rao A, Ruperto N . Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S118-57. PMC: 3748930. DOI: 10.1002/acr.20532. View

15.

Bendewald M, Wetter D, Li X, Davis M . Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010; 146(1):26-30. PMC: 2886726. DOI: 10.1001/archdermatol.2009.328. View

16.

Phillips B, Zilko P, Garlepp M, Mastaglia F . Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve. 1998; 21(12):1668-72. DOI: 10.1002/(sici)1097-4598(199812)21:12<1668::aid-mus7>3.0.co;2-#. View

17.

Airio A, Kautiainen H, Hakala M . Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006; 25(2):234-9. DOI: 10.1007/s10067-005-1164-z. View

18.

Riewpaiboon A . Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thai. 2014; 97 Suppl 5:S127-34. View

19.

Ponyi A, Constantin T, Balogh Z, Szalai Z, Borgulya G, Molnar K . Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol. 2005; 23(1):50-6. View

20.

Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J . Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000; 29(2):95-102. DOI: 10.1080/030097400750001897. View